Keros Therapeutics Is Maintained at Sector Outperform by Scotiabank

Dow Jones14:56 ET · Ratings

Keros Therapeutics Price Target Cut to $44.00/Share From $77.00 by Scotiabank

Dow Jones14:56 ET · Ratings

Jefferies Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $23

Moomoo NewsDec 13 10:32 ET · Ratings

Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating

Moomoo NewsDec 13 08:31 ET · Ratings

Scotiabank Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $44

Moomoo NewsDec 13 08:31 ET · Ratings

A Quick Look at Today's Ratings for Keros Therapeutics(KROS.US), With a Forecast Between $47 to $84

Moomoo NewsDec 13 08:00 ET · Ratings